Articles tagged with Macular Degeneration
Researchers found that rheumatoid arthritis patients treated with anti-inflammatory drugs were 10 times less likely to develop age-related macular degeneration. This study suggests that anti-inflammatory drugs may be a promising approach for treating the intractable disease.
A recent study published in the British Journal of Ophthalmology found that smoking doubles the risk of age-related macular degeneration, a leading cause of blindness in the UK. The study suggests that up to 30,000 cases of visual impairment may be attributable to smoking, highlighting the importance of quitting smoking and promoting p...
Researchers at Yale University have identified a common gene variant associated with age-related macular degeneration in Caucasian patients. The variant, found on chromosome 1, is linked to the complement factor H (CFH) gene and affects individuals over 60 years old.
Researchers have identified a gene mutation in Complement Factor H as a key factor in the development of age-related macular degeneration. This complex disease affects millions of Americans, with family history being a significant risk factor.
A common gene variant in the complement factor H (CFH) gene is associated with a 43% increase in risk of age-related macular degeneration. This finding sheds light on the disease's underlying mechanisms and could lead to new therapeutic approaches. Understanding the role of CFH may ultimately enable early detection and prevention of AMD.
Researchers at the University of Utah Health have created a genetically engineered mouse model that closely mimics age-related macular degeneration and Stargardt disease. The study provides a promising platform for testing treatment strategies such as cell transplantation, gene therapy, and pharmaceuticals.
The study developed mice with a mutant form of ELOVL4, which causes significant lipofuscin accumulation and photoreceptor death, closely resembling human AMD and STGD. This model now permits testing of potential therapies for the dry version of age-related AMD and STGD.
The study found that dietary supplement use increased from 14.2% in 1998-1999 to 18.8% in 2002, with a rise in multivitamin products containing antioxidants like lutein and lycopene. The acceptance of herbal supplements has become more mainstream, and marketing strategies have expanded to prevent chronic diseases.
A growing epidemic of wet AMD is expected to double diagnoses by 2020, with new treatments in late-phase clinical trials or pending FDA approval showing promise for stabilizing the disease and preserving vision. Innovations in biotechnology offer new options for patients, including anti-VEGF, anti-angiogenic, and angiostatic treatments.
The study confirms that patients benefit from two years of treatment with Macugen for wet AMD, demonstrating a statistically significant 45% treatment benefit. Longer-term use may be beneficial for patients suffering from this chronic disease.
Researchers found genetic mutations in fibulin genes, specifically FBLN5, that could contribute to AMD. However, these changes were not statistically significant, and the study highlights the importance of precise search methods for genetic causes.
Researchers have confirmed three previously suggested loci and identified two new ones for potential AMD genes on chromosomes 1, 2, 5, 9, 22. The study used high-resolution genome scans to narrow the search for AMD-related genes.
Biomedical engineers at Purdue used dip-pen nanolithography to create templates on retinal tissue, which can potentially improve transplant strategies for macular degeneration. The research aims to enhance the success of implanting retinal pigment epithelial cells as a treatment for this incurable eye disease.
Researchers at UCSB discovered a connection between Alzheimer's disease and age-related macular degeneration, both linked to the presence of inflammatory plaques. The study suggests that a toxic protein called amyloid beta may be the underlying culprit, stimulating an inflammation process that contributes to vision loss.
Studies found associations between high blood pressure, retinal changes, and increased risk of stroke and age-related macular degeneration. Hypertension and pulse pressure may be markers for small-vessel diseases that predict stroke and other vascular events.
A new combination therapy of photodynamic therapy and triamcinolone injection significantly improves visual acuity in patients with wet age-related macular degeneration. The treatment requires fewer retreatments compared to existing therapies, including Visudyne, and reduces costs.
Researchers have discovered a gene associated with both macular degeneration and retinitis pigmentosa, two eye diseases affecting different segments of vision. The RPGR gene is linked to early-onset macular degeneration primarily affecting males.
Raman Imaging of Human Macular Pigments demonstrates a rapid screening technique for macular degeneration using Raman spectroscopy. The method provides insight into individual variations in spatial profiles and total amounts of macular carotenoid pigments.
The FDA has approved Visudyne therapy for the treatment of wet form of age-related macular degeneration (AMD), a leading cause of blindness among people over 50. The therapy involves a two-step procedure that can be performed in a doctor's office, causing closure of abnormal blood vessels and potentially restoring central vision.
Patients with macular degeneration experienced improved moods and increased use of visual aids after completing a six-week behavioral self-management program. The program also boosted confidence in daily functioning and reduced symptoms of anxiety and depression.
Researchers have discovered a naturally occurring animal model of subretinal neovascularization, a component of age-related macular degeneration in humans. The Bst mouse develops abnormal blood vessel growth beneath the retina, similar to human ARMD, providing insights into disease mechanisms and potential therapeutic targets.
Researchers at Columbia University synthesized a derivative of vitamin A that accumulates with age in human eyes and may contribute to macular degeneration. The new synthesis allows for large-scale production of the compound, enabling further experiments to pinpoint its relationship with age-related changes in the retina.
Researchers at Oregon Health Sciences University have identified a genetic cause for age-related macular degeneration, the leading cause of blindness in the US. A large family study revealed a specific gene location on chromosome 1q25-q31, offering hope for future treatments and preventative measures.